Study of STX-003 with and without pembrolizumab for advanced solid tumors
Treatments studied
Part of Cancer, Lungs & breathing, Skin clinical trials.
This study tests an experimental drug called STX-1, given alone or with another drug that helps the immune system fight cancer. It is for people with advanced solid tumors, especially certain types of lung cancer or melanoma, who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and weigh at least 40 kg.
- You must have an advanced solid tumor that has not responded to standard therapy or for which no cure exists.
- You must have at least one tumor that can be measured on scans.
- Your cancer must be a type where approved immunotherapy is used, and specifically, you must have advanced melanoma or PD-L1 positive lung cancer for the later part of the study.
- You must be able to perform daily activities with only minor help (ECOG 0 or 1).
- Women who can have children and men with partners who can have children must agree to use birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.